These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 11356929)

  • 1. Improved pharmacokinetic properties of a polyethylene glycol-modified form of interferon-beta-1a with preserved in vitro bioactivity.
    Pepinsky RB; LePage DJ; Gill A; Chakraborty A; Vaidyanathan S; Green M; Baker DP; Whalley E; Hochman PS; Martin P
    J Pharmacol Exp Ther; 2001 Jun; 297(3):1059-66. PubMed ID: 11356929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. N-terminally PEGylated human interferon-beta-1a with improved pharmacokinetic properties and in vivo efficacy in a melanoma angiogenesis model.
    Baker DP; Lin EY; Lin K; Pellegrini M; Petter RC; Chen LL; Arduini RM; Brickelmaier M; Wen D; Hess DM; Chen L; Grant D; Whitty A; Gill A; Lindner DJ; Pepinsky RB
    Bioconjug Chem; 2006; 17(1):179-88. PubMed ID: 16417267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo pharmacology and toxicology evaluation of polyethylene glycol-conjugated interferon beta-1a.
    Hu X; Olivier K; Polack E; Crossman M; Zokowski K; Gronke RS; Parker S; Li Z; Nestorov I; Baker DP; Clarke J; Subramanyam M
    J Pharmacol Exp Ther; 2011 Sep; 338(3):984-96. PubMed ID: 21690216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-function engineering of interferon-beta-1b for improving stability, solubility, potency, immunogenicity, and pharmacokinetic properties by site-selective mono-PEGylation.
    Basu A; Yang K; Wang M; Liu S; Chintala R; Palm T; Zhao H; Peng P; Wu D; Zhang Z; Hua J; Hsieh MC; Zhou J; Petti G; Li X; Janjua A; Mendez M; Liu J; Longley C; Zhang Z; Mehlig M; Borowski V; Viswanathan M; Filpula D
    Bioconjug Chem; 2006; 17(3):618-30. PubMed ID: 16704199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and pharmacodynamics of PEGylated IFN-beta 1a following subcutaneous administration in monkeys.
    Mager DE; Neuteboom B; Jusko WJ
    Pharm Res; 2005 Jan; 22(1):58-61. PubMed ID: 15771230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel PEGylated interferon beta-1a for multiple sclerosis: safety, pharmacology, and biology.
    Hu X; Miller L; Richman S; Hitchman S; Glick G; Liu S; Zhu Y; Crossman M; Nestorov I; Gronke RS; Baker DP; Rogge M; Subramanyam M; Davar G
    J Clin Pharmacol; 2012 Jun; 52(6):798-808. PubMed ID: 21680782
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression, purification, and characterization of rat interferon-beta, and preparation of an N-terminally PEGylated form with improved pharmacokinetic parameters.
    Arduini RM; Li Z; Rapoza A; Gronke R; Hess DM; Wen D; Miatkowski K; Coots C; Kaffashan A; Viseux N; Delaney J; Domon B; Young CN; Boynton R; Chen LL; Chen L; Betzenhauser M; Miller S; Gill A; Pepinsky RB; Hochman PS; Baker DP
    Protein Expr Purif; 2004 Apr; 34(2):229-42. PubMed ID: 15003256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics, tissue distribution, excretion, and antiviral activity of pegylated recombinant human consensus interferon-α variant in monkeys, rats and guinea pigs.
    Cai Y; Zhang Z; Fan K; Zhang J; Shen W; Li M; Si D; Luo H; Zeng Y; Fu P; Liu C
    Regul Pept; 2012 Jan; 173(1-3):74-81. PubMed ID: 21985916
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PEGylated recombinant human interferon-ω as a long-acting antiviral agent: structure, antiviral activity and pharmacokinetics.
    Yu W; Yu C; Wu L; Fang T; Qiu R; Zhang J; Yu T; Fu L; Chen W; Hu T
    Antiviral Res; 2014 Aug; 108():142-7. PubMed ID: 24936771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Site-specific PEGylation enhances the pharmacokinetic properties and antitumor activity of interferon beta-1b.
    Lee JI; Eisenberg SP; Rosendahl MS; Chlipala EA; Brown JD; Doherty DH; Cox GN
    J Interferon Cytokine Res; 2013 Dec; 33(12):769-77. PubMed ID: 23962003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of copper-catalyzed azide-alkyne cycloaddition for increased in vivo efficacy of interferon β-1b by site-specific PEGylation.
    Nairn NW; Shanebeck KD; Wang A; Graddis TJ; VanBrunt MP; Thornton KC; Grabstein K
    Bioconjug Chem; 2012 Oct; 23(10):2087-97. PubMed ID: 22988919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-acting forms of Sonic hedgehog with improved pharmacokinetic and pharmacodynamic properties are efficacious in a nerve injury model.
    Pepinsky RB; Shapiro RI; Wang S; Chakraborty A; Gill A; Lepage DJ; Wen D; Rayhorn P; Horan GS; Taylor FR; Garber EA; Galdes A; Engber TM
    J Pharm Sci; 2002 Feb; 91(2):371-87. PubMed ID: 11835197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced circulating half-life and antitumor activity of a site-specific pegylated interferon-alpha protein therapeutic.
    Bell SJ; Fam CM; Chlipala EA; Carlson SJ; Lee JI; Rosendahl MS; Doherty DH; Cox GN
    Bioconjug Chem; 2008 Jan; 19(1):299-305. PubMed ID: 18020402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic and pharmacodynamic comparison of two "pegylated" interferon alpha-2 formulations in healthy male volunteers: a randomized, crossover, double-blind study.
    García-García I; González-Delgado CA; Valenzuela-Silva CM; Díaz-Machado A; Cruz-Díaz M; Nodarse-Cuní H; Pérez-Pérez O; Bermúdez-Badell CH; Ferrero-Bibilonia J; Páez-Meireles R; Bello-Rivero I; Castro-Odio FR; López-Saura PA;
    BMC Pharmacol; 2010 Nov; 10():15. PubMed ID: 21092287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic properties of a 40 kDa branched polyethylene glycol-modified form of consensus interferon-alpha (PEG-CIFN) in rhesus monkeys.
    Du Y; Tian H; Gao XD; Yao WB
    Biopharm Drug Dispos; 2008 Nov; 29(8):481-4. PubMed ID: 18985796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PEGylation of proteins in organic solution: a case study for interferon beta-1b.
    Peng F; Wang Y; Sun L; Liu Y; Hu T; Zhang G; Ma G; Su Z
    Bioconjug Chem; 2012 Sep; 23(9):1812-20. PubMed ID: 22873735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A long-acting, highly potent interferon alpha-2 conjugate created using site-specific PEGylation.
    Rosendahl MS; Doherty DH; Smith DJ; Carlson SJ; Chlipala EA; Cox GN
    Bioconjug Chem; 2005; 16(1):200-7. PubMed ID: 15656592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-acting interferon-alpha 2a modified with a trimer-structured polyethylene glycol: preparation, in vitro bioactivity, in vivo stability and pharmacokinetics.
    Jo YW; Youn YS; Lee SH; Kim BM; Kang SH; Yoo M; Choi EC; Lee KC
    Int J Pharm; 2006 Feb; 309(1-2):87-93. PubMed ID: 16406701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and systemic absorption of pulmonary delivered human IFN-beta1a in the nonhuman primate: comparison with subcutaneous dosing.
    Martin PL; Vaidyanathan S; Lane J; Rogge M; Gillette N; Niggemann B; Green J
    J Interferon Cytokine Res; 2002 Jun; 22(6):709-17. PubMed ID: 12162883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of a non-covalent cell-penetrating peptide strategy to enhance the nasal delivery of interferon beta and its PEGylated form.
    Iwase Y; Kamei N; Khafagy el-S; Miyamoto M; Takeda-Morishita M
    Int J Pharm; 2016 Aug; 510(1):304-10. PubMed ID: 27343364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.